| Hu, Bo |
NCT05585151: High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized Study |
|
|
| Recruiting | 4 | 200 | RoW | Evolocumab 140 MG/ML, Intensive statin treatment | Wuhan Union Hospital, China | Cerebral Atherosclerosis | 04/24 | 10/24 | | |
| Active, not recruiting | 4 | 800 | RoW | Sodium Oligomannate Capsules (GV-971) | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 06/25 | | |
SPAIR-2, NCT05159947: SPT-07A Injection in Patients With Acute Ischemic Stroke (AIS): A Phase III Clinical Trial |
|
|
| Recruiting | 3 | 1112 | RoW | SPT-07A injection, placebo | Wuhan Union Hospital, China, Suzhou Huyun New Drug Research and Development Co., Ltd, Shanghai Canming Pharmaceutical Technology Co., Ltd, Beijing Haijinge Pharmaceutical Technology Co., Ltd, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Xiang Yang NO.1 People's Hospital, Xiangyang Central Hospital, Wuhan NO. 4 hospital, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Central Hospital, Yan'an University Xianyang hospital Co., Ltd, Hengshui People's Hospital, Inner Mongolia Baogang Hospital, Daqing oilfield general hospital, The Fourth Affiliated Hospital of Harbin Medical University, The First Hospital of Jilin University, Meihekou Central Hospital, Jiangsu Taizhou People's Hospital, Tianjin People's Hospital, Taizhou Hospital, Zhejiang Taizhou hospital, The First Affiliated Hospital of Nanhua University, Affiliated hospital of jining medical college, Zhongshan Hospital Xiamen University, Neijiang Second People's Hospital, Tancheng first people's Hospital, The Affiliated Hospital of Qingdao University, Taian Central Hospital, Weihai Municipal Hospital, Nanyang nanshai hospital, Dezhou People's Hospital, The First Affiliated Hospital of Nanyang Medical College, Deyang People's Hospital, Yantai Yuhuangding Hospital, Qingdao Central Hospital, Fukuang General Hospital of Liaoning health industry group, Xi'an Gaoxin Hospital, Affiliated Hospital of Jiaxing University, Fujian Zhangzhou hospital, The Affiliated Hospital of Inner Mongolia Medical University, Daqing people's Hospital, Hainan People's Hospital, Qujing first people's Hospital, The Third Affiliated Hospital of Qiqihar Medical College, The First Affiliated Hospital of Hebei North University, Linfen Central Hospital, Xuancheng people's hospital, The First Affiliated Hospital of Shihezi University Medical College, Guangzhou Red Cross Hospital, People's Hospital of Wuhan University, Wuhan Central Hospital, Jingzhou Central Hospital, Huanggang Central Hospital, Sinopharm Dongfeng General Hospital, Changjiang Shipping General Hospital, Yichang Central People's Hospital, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Xiangtan Central Hospital | Stroke, Acute | 01/24 | 01/24 | | |
| Recruiting | 3 | 2100 | Europe, Canada, Japan, US, RoW | Rimegepant/BHV3000, Matching placebo | Pfizer | Pediatric Migraine | 01/29 | 01/29 | | |
NCT05811442: Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease |
|
|
| Recruiting | 2a | 60 | RoW | 50561 high dose, 50561 low dose, Placebo | Beijing Joekai Biotechnology LLC | Alzheimer's Disease | 05/24 | 06/24 | | |
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2 | 162 | RoW | BAT4406F Injection, BAT4406F Placebos | Bio-Thera Solutions | Optic Neuromyelitis Spectrum Disease | 05/25 | 05/26 | | |
NCT05359601: Infusion Set Replacement Intervals for Critically Ill Patients |
|
|
| Recruiting | N/A | 1240 | RoW | Infusion set replacement intervals | Zhongnan Hospital | Critical Illness | 12/25 | 06/26 | | |
| Not yet recruiting | N/A | 300 | NA | smartphone related behaviors | Tang-Du Hospital | Social Media, Mental Health Disorder, Brain Imaging | 10/23 | 06/24 | | |
| Recruiting | N/A | 30 | RoW | Drug screen with PDO/PDO-TIL/PDOTS | Shanghai Zhongshan Hospital | Liver Cancer, Metastatic Liver Cancer | 06/26 | 06/26 | | |
| Zhang, Tao |
NCT05175001: Efficacy of Compound Betamethasone Injection Combined With Ropivacaine in Ultrasound-guided Thoracic Paravertebral Nerve Block for Chronic Post-thoracotomy Pain |
|
|
| Recruiting | 4 | 100 | RoW | Diprospan, Compound Betamethasone Injection, Ropivacaine | Affiliated Hospital of Nantong University | Chronic Pain | 06/22 | 01/23 | | |
PIONEER, NCT05029453: Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy |
|
|
| Not yet recruiting | 4 | 60 | RoW | Apatinib | Wuhan Union Hospital, China, Jiangsu HengRui Medicine Co., Ltd. | Gastric Cancer, Randomized Controlled Study | 12/22 | 03/23 | | |
NCT05598177: Effect of Dexmedetomidine Preconditioning on Myocardial Ischemia-reperfusion Injury in Patients Undergoing Open Heart Surgery With Cardiopulmonary Bypass |
|
|
| Completed | 4 | 64 | RoW | dexmedetomidine, Placebo | Affiliated Hospital of Nantong University | Ischemia-Reperfusion Injury | 05/23 | 12/23 | | |
NCT05922605: Analgesic Effects of Caudal S-ketamine for Supplementation of Ropivacaine Caudal Analgesia in Children With Hypospadias |
|
|
| Recruiting | 4 | 44 | RoW | S-ketamine & Ropivacaine, Ropivacaine | Tao Zhang | Postoperative Analgesia, S-ketamine, Pediatrics, Caudal Block, Hypospadias | 04/25 | 05/25 | | |
UNION, NCT04928807: Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer |
|
|
| Active, not recruiting | 3 | 231 | RoW | Short course radiotherapy sequential camrelizumab and chemotherapy | Wuhan Union Hospital, China, Jiangsu HengRui Medicine Co., Ltd. | Rectal Cancer | 03/23 | 03/26 | | |
NCT03399253: Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor |
|
|
| Recruiting | 3 | 120 | RoW | surgery, chemotherapy, XELOX | Sun Yat-sen University | Gastric Cancer | 11/22 | 12/25 | | |
NCT03399110: XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC) |
|
|
| Active, not recruiting | 3 | 1032 | RoW | Oxaliplatin, Eloxatin, Capecitabine, Xeloda | Fudan University | Gastric Cancer | 08/26 | 08/26 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
NCT04687631: Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases |
|
|
| Recruiting | 3 | 508 | RoW | mFOLFOXIRI plus Cetuximab, mFOLFOXIRI Plus Bevacizumab | Fudan University | Colorectal Cancer, Liver Metastases | 03/25 | 09/27 | | |
BECOME2, NCT04781270: mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases |
|
|
| Recruiting | 3 | 308 | RoW | mFOLFOXIRI regimen, mFOLFOX regimen, Bevacizumab | Fudan University | Colorectal Carcinoma, Liver Metastases | 03/24 | 03/26 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT06753890: Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern) |
|
|
| Not yet recruiting | 3 | 520 | RoW | Changkang granules, Changkang Granules placebo | Tasly Pharmaceutical Group Co., Ltd | Diarrhea-predominant Irritable Boewl Syndrome | 11/26 | 12/26 | | |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer |
|
|
| Active, not recruiting | 3 | 878 | RoW | JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy | Shanghai Junshi Bioscience Co., Ltd. | Gastric or Esophagogastric Junction Adenocarcinoma | 06/26 | 07/28 | | |
NCT05844150: A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC |
|
|
| Recruiting | 2/3 | 445 | RoW | PM8002, Platinum, Atezolizumab, Etoposide | Biotheus Inc. | SCLC | 06/25 | 12/25 | | |
NCT03135652: Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation |
|
|
| Withdrawn | 2 | 120 | RoW | adjuvant SBRT, radiotherapy, Chemotherapy, neoadjuvant chemotherapy and adjuvant chemotherapy | Wuhan Union Hospital, China | Radiotherapy, Colorectal Cancer, Liver Metastases | 06/21 | 06/23 | | |
MCRC-LC1, NCT03142282: Consolidative Radiotherapy Plus Maintenance Chemotherapy for Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 200 | RoW | maintenance chemotherapy, Consolidative Radiotherapy | Wuhan Union Hospital, China | Metastatic Colorectal Cancer, Radiotherapy | 08/21 | 08/24 | | |
NCT04563975: Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 54 | RoW | Toripalimab, JS001, Docetaxel, Taxotere, nab-paclitaxel, AI YUE | Tao Zhang | Gastric Cancer Stage IV | 12/22 | 05/23 | | |
NCT05387681: Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastric |
|
|
| Not yet recruiting | 2 | 35 | NA | Envafolimab, Endostatin | Wuhan Union Hospital, China | Gastric/Gastroesophageal Junction Adenocarcinoma, Radiotherapy, Immunotherapy | 07/23 | 12/25 | | |
NCT05202236: A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy |
|
|
| Recruiting | 2 | 20 | RoW | pemigatinib | Wuhan Union Hospital, China | Gastric and Colorectal Cancer | 10/23 | 10/24 | | |
UNION PRECISION-I, NCT06234007: Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study |
|
|
| Recruiting | 2 | 45 | RoW | Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine | Wuhan Union Hospital, China, Renmin Hospital of Wuhan University | Locally Advanced Rectal Cancer | 12/24 | 12/27 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT06487429: Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer |
|
|
| Recruiting | 2 | 28 | RoW | Short range radiotherapy with sequential Disitamab Vedotin combined with S-1 and xindilizumab | Wuhan Union Hospital, China, RemeGen Co., Ltd. | Gastric Cancer | 05/26 | 05/28 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
AK112-IIT-004, NCT06491472: Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer |
|
|
| Recruiting | 2 | 36 | RoW | Ivonescimab, AK112/SMT112, Gemcitabine, Nab paclitaxel, SBRT | Wuhan Union Hospital, China, Akesobio | Pancreatic Cancer | 07/26 | 07/27 | | |
NCT06542588: Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC |
|
|
| Recruiting | 2 | 29 | RoW | HLX07(anti EGFR antibody) and Serplulimab(anti PD-1 antibody), CAPOX | Wuhan Union Hospital, China | Rectal Cancer | 12/25 | 12/26 | | |
NCT06802666: Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 45 | RoW | short-course radiotherapy, SCRT, Ivonescimab, AK112, capecitabine, oxaliplatin, TME surgery | Wuhan Union Hospital, China | Locally Advanced Rectal Cancer, Neoadjuvant Therapy | 09/26 | 12/27 | | |
NCT06111274: A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 82 | RoW | Pimicotinib (ABSK021), Gemcitabine, nab-Pacilitaxel, Toripalimab | Abbisko Therapeutics Co, Ltd | Advanced Pancreatic Cancer | 12/25 | 12/26 | | |
NCT05747716: SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC |
|
|
| Not yet recruiting | 2 | 44 | RoW | SBRT, Fruquintinib, Cadonilimab | Wuhan Union Hospital, China | Metastatic Colorectal Cancer | 12/26 | 12/26 | | |
NCT04231552: Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer |
|
|
| Active, not recruiting | 1/2 | 30 | RoW | Camrelizumab, Radiotherapy with CAPOX+ Camrelizumab following surgical therapy | Wuhan Union Hospital, China | Rectal Cancer, Radiotherapy, Immunotherapy | 09/20 | 09/23 | | |
NCT06266143: A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer |
|
|
| Active, not recruiting | 1/2 | 71 | RoW | Y101D | Wuhan YZY Biopharma Co., Ltd. | Advanced Pancreatic Adenocarcinoma | 07/24 | 12/24 | | |
NCT05653180: IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer |
|
|
| Recruiting | 1/2 | 20 | RoW | IBI310, sintilimab, IBI308 | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Biliary Tract Cancer | 12/23 | 06/24 | | |
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors |
|
|
| Recruiting | 1/2 | 133 | RoW | KC1036 | Beijing Konruns Pharmaceutical Co., Ltd. | Digestive System Tumors | 10/25 | 12/25 | | |
NCT05747729: A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma. |
|
|
| Not yet recruiting | 1/2 | 60 | RoW | Surufatinib and Serplulimab | Wuhan Union Hospital, China | Neuroendocrine Carcinoma | 02/25 | 02/26 | | |
| Recruiting | 1/2 | 364 | RoW | SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor therapies | Jiangsu HengRui Medicine Co., Ltd. | HER2-expressing Advanced Solid Tumors | 11/26 | 12/26 | | |
NCT06144385: A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 20 | RoW | CAR-GPC3 T cells, JWCAR204 | Shanghai Ming Ju Biotechnology Co., Ltd. | Liver Carcinoma, Hepatic Cell Carcinoma | 03/24 | 12/24 | | |
NCT06166472: A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor |
|
|
| Not yet recruiting | 1 | 72 | RoW | AK132 | Akeso | Advanced Malignant Solid Tumor | 04/26 | 07/26 | | |
NCT05169697: A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors |
|
|
| Completed | 1 | 6 | RoW | A:YH002+YH001, B:YH002+YH001, YH002+YH001 | Eucure (Beijing) Biopharma Co., Ltd | Advanced Solid Tumor | 07/23 | 07/23 | | |
NCT05441046: Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 120 | RoW | Genakumab, Tislelizumab | GeneScience Pharmaceuticals Co., Ltd. | Malignant Solid Tumors | 06/24 | 03/25 | | |
| Recruiting | 1 | 556 | RoW | IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 06/25 | 12/26 | | |
NCT06484556: NW-301 TCR-T in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1 | 9 | RoW | NW-301V, NW-301D | Tao Zhang, Neowise Biotechnology | Tumor, Solid | 06/26 | 06/27 | | |
NCT06437873: Long-term Survival Outcomes of Total Thyroidectomy and Radioactive Iodine Therapy in Unilateral T3/T4 FTC |
|
|
| Completed | N/A | 2957 | NA | Total Thyroidectomy (TT), Radioactive iodine treatment(RAIT) | Dezhou Hospital Qilu Hospital of Shandong University | Follicular Thyroid Cancer, SEER Database Analysis | 12/20 | 05/24 | | |
| Completed | N/A | 3068 | NA | Different Pathological Types (FTC vs PTC), Different Pathological Types | Dezhou Hospital Qilu Hospital of Shandong University | Pediatric and Adolescent Differentiated Thyroid Carcinoma, SEER Database Analysis | 12/20 | 08/24 | | |
NCT03426514: Three-port Versus Conventional Laparoscopic Surgery for Colorectal Cancer |
|
|
| Recruiting | N/A | 282 | RoW | Three-port Laparoscopic Surgery, Conventional Laparoscopic Surgery | Ruijin Hospital | Colorectal Cancer | 03/20 | 03/25 | | |
NCT05280860: Effect of Bilateral RSB on Postoperative Delirium in Elderly Patients Undergoing Laparoendoscopic Single-site Surgery |
|
|
| Recruiting | N/A | 320 | RoW | ultrasound-guided bilateral rectus sheath block | Affiliated Hospital of Nantong University | Delirium in Old Age, Hernia, Inguinal, Cholecystolithiasis | 12/22 | 12/22 | | |
NCT04360577: Acupuncture for QoL and Symptoms in Gastric Cancer During Adjuvant Chemotherapy |
|
|
| Completed | N/A | 240 | RoW | acupuncture | Guangzhou University of Traditional Chinese Medicine, First Affiliated Hospital, Sun Yat-Sen University, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Sixth Affiliated Hospital, Sun Yat-sen University, Southern Medical University, China, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Guangzhou Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Fifth Affiliated Hospital, Sun Yat-Sen University, First People's Hospital of Foshan, Yuebei People's Hospital | Stomach Neoplasms | 03/23 | 05/23 | | |
NCT05325827: Effect of Ultrasound-guided H-FICB in Patients Undergoing Arthroscopic Knee Surgery |
|
|
| Recruiting | N/A | 44 | RoW | ultrasound-guided high fascia iliaca compartment block | Affiliated Hospital of Nantong University | Knee Disease, Delirium | 12/22 | 02/23 | | |
NCT05533970: Ultrasound-guided H-FICB for Arthroscopic Knee Surgery： What is the Optimal Dose of Dexmedetomidine? |
|
|
| Completed | N/A | 120 | RoW | ultrasound-guided high fascia iliaca compartment block | Affiliated Hospital of Nantong University | Knee Disease, Quality of Recovery | 12/22 | 01/23 | | |
NCT06141421: A Real-World Study to Evaluate the Clinical Performance and Safety of da Vinci SP Surgical System for Single-Port Colorectal Surgeries（SPiM-RWS-CR） |
|
|
| Completed | N/A | 15 | RoW | procedure | Ruijin Hospital | Single-Port Colorectal Surgeries | 08/24 | 08/24 | | |
NCT05820503: Effect of Nerve Block Under Ultrasound on Postoperative Prognosis in Children |
|
|
| Completed | N/A | 112 | RoW | Ultrasound-guided lower abdominis rectus sheath block, Local anesthesia infiltration | Affiliated Hospital of Nantong University | Quality of Recovery | 10/23 | 10/23 | | |
NCT06189183: Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection |
|
|
| Recruiting | N/A | 50 | RoW | Adjuvant Hypofractionation Radiotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Thymus Neoplasms | 12/30 | 12/40 | | |
| Recruiting | N/A | 174 | RoW | Upadacitinib | Xiang Gao | Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis | 12/28 | 12/28 | | |
NCT06508008: Rapid and Safe Sputum Suction Method Validation |
|
|
| Recruiting | N/A | 900 | RoW | continuous negative pressure suction, Intermittent negative pressure sputum suction through oral pharyngeal airway | Affiliated Hospital of Nantong University | Sputum | 07/24 | 08/24 | | |
NCT06163092: Chronic Endometritis and Benefits of Antibiotics in Women With Recurrent Miscarriage |
|
|
| Not yet recruiting | N/A | 175 | RoW | | Chinese University of Hong Kong | Recurrent Miscarriage | 01/26 | 01/27 | | |
NCT06417749: MIND Diet and Cognitive Function in Middle-aged and Older Adults |
|
|
| Not yet recruiting | N/A | 1200 | RoW | Control arm, Intervention arm | Zhejiang University, Shandong University | Cognitive Function, Dementia | 05/25 | 10/25 | | |
NCT05613049: Confounding Factors of Chronic Endometritis in Women With Reproductive Failure |
|
|
| Recruiting | N/A | 720 | RoW | | Chinese University of Hong Kong | IVF | 07/27 | 01/28 | | |
| Dong, Xiaorong |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
NCT06280196: A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC |
|
|
| Recruiting | 3 | 676 | RoW | BAT3306, Pembrolizumab Injection, EU-Keytruda®, US-Keytruda®, Pemetrexed, Pemetrexed Fresenius Kabi, Carboplatin, Carboplatin Kabi | Bio-Thera Solutions | Carcinoma, Non-Small-Cell Lung | 07/27 | 10/28 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT04106180: SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC |
|
|
| Recruiting | 2 | 63 | RoW | GM-CSF, Sintilimab, SBRT, Stereotactic body radiation therapy | Fudan University | NSCLC Stage IV | 08/22 | 08/23 | | |
NCT05738317: Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment |
|
|
| Recruiting | 2 | 45 | RoW | Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel | Xiaorong Dong | Non-small Cell Lung Cancer | 06/23 | 12/24 | | |
NCT06668103: A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib |
|
|
| Recruiting | 2 | 54 | RoW | ABSK043 in combination with Firmonertinib | Abbisko Therapeutics Co, Ltd | Non-Small Cell Lung Cancer With EGFR Mutation | 12/27 | 06/28 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
NCT06020066: SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI |
|
|
| Recruiting | 2 | 202 | RoW | EGFR-TK Inhibitor, Stereotactic radiotherapy | Fudan University | Brain Metastases, Non-small Cell Lung Cancer | 08/28 | 08/29 | | |
| Recruiting | 1/2 | 310 | RoW | ICP-723 | Beijing InnoCare Pharma Tech Co., Ltd. | Solid Tumors | 06/25 | 02/28 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT06144671: GT201 Injection For The Treatment Of Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 18 | RoW | GT201 | Grit Biotechnology | Solid Tumor, Adult | 09/26 | 09/26 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
NCT04322006: A Phase I/II Study of TJ004309 for Advanced Solid Tumor |
|
|
| Active, not recruiting | 1/2 | 376 | RoW | TJ004309, Toripalimab | TJ Biopharma Co., Ltd. | Advanced Solid Tumor | 12/24 | 12/24 | | |
NCT05552781: H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC |
|
|
| Recruiting | 1/2 | 76 | RoW | H002 capsule, H002 | RedCloud Bio, R&G Pharma Studies Co.,Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/25 | | |
NCT05367778: Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 176 | RoW | HS-10370 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 04/25 | 04/26 | | |
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 902 | US, RoW | DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327 | DualityBio Inc., BioNTech SE | Advanced Solid Tumor | 06/25 | 06/25 | | |
| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT04825392: A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | HX008 | Taizhou Hanzhong biomedical co. LTD | Advanced Solid Tumor | 05/21 | 12/21 | | |
NCT04448379: Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 48 | RoW | JMT101, Afatinib or Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 12/21 | 06/22 | | |
NCT04489862: αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors |
|
|
| Recruiting | 1 | 10 | RoW | αPD1-MSLN-CAR T cells | Wuhan Union Hospital, China, Shanghai Cell Therapy Group Co.,Ltd | Non-small-cell Lung Cancer, Mesothelioma | 06/22 | 12/22 | | |
NCT05025358: A Study of LP-118 in Patients with Advanced Tumors |
|
|
| Active, not recruiting | 1 | 96 | RoW | LP-118 tablet, NWP-4-76 | Guangzhou Lupeng Pharmaceutical Company LTD. | Solid Tumor, Lymphoma, Non-Hodgkin | 01/25 | 12/25 | | |
NCT05508334: A Study to Assess the Safety and Tolerability of RC88 for Patients with Advanced Solid Tumours |
|
|
| Active, not recruiting | 1 | 81 | RoW | RC88, The injectable RC88 | RemeGen Co., Ltd. | Advanced Solid Tumours | 06/25 | 12/25 | | |
NCT05430386: Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC |
|
|
| Recruiting | 1 | 174 | RoW | HS-10241, Almonertinib | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Non Small Cell Lung Cancer | 12/23 | 12/23 | | |
| Recruiting | 1 | 31 | US, RoW | AN4005-dose level 0, AN4005-dose level 1, AN4005-dose level 2, AN4005-dose level 3, AN4005-dose level 4, AN4005-food effect | Adlai Nortye Biopharma Co., Ltd. | Advanced Solid Tumor, Advanced Lymphoma | 08/25 | 12/25 | | |
NCT06225804: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 164 | US, RoW | ABSK112, EGFR Exon20 inhibitor | Abbisko Therapeutics Co, Ltd | Non-Small Cell Lung Cancer | 03/27 | 03/28 | | |
KN-8701, NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors |
|
|
| Recruiting | 1 | 400 | Europe, US, RoW | KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib | Pierre Fabre Medicament | Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma | 12/24 | 12/25 | | |
NCT05244551: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 85 | US, RoW | ABSK061 | Abbisko Therapeutics Co, Ltd | Solid Tumor | 04/25 | 04/25 | | |
NCT05737589: Circulating Tumor DNA and T Cell Repertoire Predict Radiotherapeutic Outcomes in NSCLC Patients With Brain Metastasis |
|
|
| Not yet recruiting | N/A | 50 | RoW | Whole-brain radiotherapy, Stereotactic radiotherapy | Xiaorong Dong | Carcinoma, Non-Small-Cell Lung, Brain Metastases | 02/24 | 10/24 | | |
NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | N/A | 80 | RoW | Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations | 06/23 | 08/23 | | |
| Huang, Anbin |
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | 2 | 186 | RoW | Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Systemic Lupus Erythematosus, SLE | 08/25 | 05/26 | | |
NCT05998759: Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia |
|
|
| Recruiting | 2 | 296 | RoW | Telitacicept, recombinant human B lymphocyte stimulating factor receptor-Fc fusion protein, Recombinant Human B Lymphocyte(RC18), Tai'ai®, Placebo, Placebo control, control | Beijing Hospital, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Peking University People's Hospital, Peking University Third Hospital, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Wuhan Union Hospital, China, Second Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The Affiliated Hospital of Inner Mongolia Medical University, First Hospital of China Medical University, Shandong Provincial Hospital, Changhai Hospital, RenJi Hospital, Shanxi Bethune Hospital, West China Hospital, Institute of Hematology & Blood Diseases Hospital, China, Tianjin First Central Hospital, Tianjin Medical University General Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The First People's Hospital of Yunnan | Connective Tissue Diseases, Thrombocytopenia | 12/25 | 12/25 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
